PFE Pfizer Inc

Q2 2025 10-Q

Filed: Aug 5, 2025Period ending Jun 29, 2025

Health Care

Pharmaceutical PreparationsSEC EDGAR

Pfizer Inc (PFE) 10-Q quarterly report for Q2 2025, filed with SEC EDGAR on Aug 5, 2025 for the fiscal period ending Jun 29, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.

AI Filing Analysis
Q2 2025 10-Q

Risk Factors

• New risk: OBBBA tax law enacted July 4, 2025, with further guidance pending, potentially impacting tax and tariff policies globally
• Material update: Reduced demand and excess inventory risk for COVID-19 products amid endemic seasonal market conditions and shifting EUA status

+3 more insights

Quarterly Financial Summary
XBRL

Revenue

$14.7B

▲ +10.3% YoY▲ +6.8% QoQ

Net Income

$2.9B

▲ +6997.6% YoY▼ -1.9% QoQ

Net Margin

19.9%

▲ +1955bp YoY▼ -177bp QoQ

EPS (Diluted)

$0.51

▼ -1.9% QoQ

Operating Cash Flow

-$582M

▲ +67.3% YoY▼ -124.9% QoQ

Source: XBRL data from Pfizer Inc Q2 2025 10-Q filing on SEC EDGAR. All figures in USD.

Other Pfizer Inc Quarterly Reports

Q3 2025 10-Q

Get deeper insights on Pfizer Inc

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.